Investor Relations
Press Releases
Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
Read More
Advaxis to Receive $1.6 Million Through New Jersey Technology Business Tax (NOL) Program
Read More
Advaxis Presents New Data Featuring Its Lm Technology™ at the Society for Immunotherapy of Cancer 2015 Annual Meeting
Read More
Advaxis to Present at the Jefferies Autumn 2015 Global Healthcare Conference
Read More
Advaxis Provides Additional Information on Clinical Hold
Read More
Advaxis Launches MINE(TM) Collaboration
Read More
Advaxis’s Cancer Immunotherapies to be Featured in Three Poster Presentations at the 2015 SITC Annual Meeting
Read More
Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac
Read More
First Human Patient Treated in Phase 1b Study of Advaxis's ADXS-HER2 in HER2 Expressing Solid Tumors
Read More
Advaxis's Axalimogene Filolisbac (ADXS-HPV) Showed 38.5 Percent 12-Month Survival in Patients With Persistent/Recurrent Metastatic Cervical Cancer
Read More
